LCZ696
General (including evidence of efficacy) LCZ696 (sacubitril/valsartan) is a member of a new class of agents called angiotensin receptor-neprilysin inhibitors (ARNIs) which combine a neprilysin inhibitor and angiotensin receptor blocker (ARB). LCZ696 is currently indicated for treating patients with heart failure with reduced ejection fraction (HFrEF) in place of an angiotensin converting enzyme (ACE) inhibitor…
